GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Medtronic, Inc. (MDT) [hlAlert]

Rating:
Neutral MDT
up 12.09 %

Medtronic, Inc. (MDT) downgraded to Neutral by Credit Suisse

Posted on: Thursday,  May 16, 2013  8:25 AM ET by Credit Suisse

Credit Suisse rated Neutral Medtronic, Inc. (NYSE: MDT) on 05/16/2013. Previously Credit Suisse rated Outperform Medtronic, Inc. (NYSE: MDT) on 01/17/2013.,
when the stock price was $44.47. Since then, Medtronic, Inc. has gained 12.10% as of 05/16/2013's recent price of $49.85.
If you would have followed the previous Credit Suisse's recommendation on MDT, you would have gained 12.09% of your investment in 119 days.

Medtronic, Inc. (Medtronic) is a global player in medical technology. The Company operates in seven segments that manufacture and sell device-based medical therapies: Cardiac Rhythm Disease Management, Spinal, CardioVascular, Neuromodulation, Diabetes, Surgical Technologies and Physio-Control. Through these seven segments, the Company develops, manufactures and markets its medical devices in more than 120 countries. Its primary products include those for cardiac rhythm disorders, cardiovascular disease, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive disorders, diabetes, and ear, nose and throat conditions. The primary markets for products are the United States, Western Europe and Japan. In July 2008, it acquired Restore Medical, Inc. In November 2008, Medtronic acquired CryoCath Technologies Inc. In February 2009, it acquired Ablation Frontiers, Inc. and Ventor Technologies Ltd. In April 2009, Medtronic acquired CoreValve, Inc.

Excellence in equity and fixed income research is a hallmark of Credit Suisse. Globally, our equity research analysts provide in-depth coverage of over 2,500 companies and engage in a knowledge-sharing, value added culture that has yielded the most insightful product for our customers and tremendous competitive results. Additionally, Credit Suisse's powerful macro-economic and debt strategy teams integrate the bank's comprehensive company research with keen market perspectives of the ever-shifting investment terrain.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/16/2013 8:25 AM Hold
None
49.85
as of 12/13/2013
1 Week   
1 Month   
3 Months   
1 YTD up  21.52 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/17/2013 8:25 AM Buy
None
44.47
11/5/2009 8:25 AM Buy
None
37.94
6/3/2009 8:25 AM Hold
None
35.19 39.00
11/7/2007 11:25 AM Hold
None
46.00 52.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy